|By Marketwired .||
|April 28, 2014 02:46 PM EDT||
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/28/14 -- Qu Biologics Inc., a biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, announced that its abstract was selected for a poster presentation at the Digestive Diseases Week conference in Chicago, Illinois on May 4, 2014. Qu Biologics' poster "Site Specific Immunomodulation - A Novel Therapeutic Approach for the Management of Moderate-to-Severe Crohn's Disease" will present results from a Crohn's disease compassionate use program of patients treated with the company's Site Specific Immunomodulators (SSIs) investigational treatment.
"SSI is a promising investigational treatment that aims to stimulate the body's innate immune system to reverse the chronic inflammation underlying many conditions, such as Crohn's disease," said Dr. Hal Gunn. "Results from the compassionate use program were very promising and supported the launch of our Phase 1/2 clinical trial for Crohn's disease, which is now recruiting. We are very pleased to share these results and the potential of SSI treatment for Crohn's disease with the gastroenterology community," Dr. Gunn commented.
A copy of the poster is available for viewing on the Digestive Diseases Week conference website. Qu Biologics will be presenting its poster at the poster session on May 4, 2014. Dr. Brian Bressler, Gastroenterologist and Qu Crohn's Trial Principal Investigator, and Dr. Hal Gunn, Qu Biologics' founder and CEO, will be available for questions during the poster session from 12:00pm-2:00pm, May 4, 2014.
Digestive Diseases Week is an annual conference attracting more than 15,000 gastroenterology professionals internationally to discuss the latest in gastrointestinal research. Abstracts are reviewed by a panel before acceptance to this highly regarded conference.
In Qu Biologics' compassionate use program, ten patients with Crohn's disease were treated with QBECO SSI. All ten patients reported improvement in symptoms while on SSI treatment. Seven of the ten patients reported full resolution of clinical symptoms with a course of SSI treatment of three months or more. Four of these patients have had ongoing sustained clinical remission after discontinuing all medications including SSI treatment. The longest case of clinical remission reported is still ongoing after more than three and a half years. These ten patients were treated under a compassionate use program, not a controlled blinded clinical trial, and therefore these results do not provide proof of benefit.
A Phase 1/2 placebo controlled randomized clinical trial is currently underway to rigorously assess effectiveness of QBECO SSI treatment. The trial, taking place at the GI Research Institute (Vancouver, Canada), is currently enrolling patients with active moderate-to-severe Crohn's disease.
About Qu Biologics
Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and immune-related disease. The company is currently recruiting participants for a Phase 1/2 clinical trial to research SSI therapy for the treatment of Crohn's disease.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease, Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally, and Chief Scientific Officer Dr. David Mullins, Assistant Professor of Microbiology and Immunology in the Norris Cotton Cancer Center at the Geisel School of Medicine at Dartmouth, and recognized expert in immune cell trafficking to tumours. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.
Qu Biologics Inc.
Jul. 28, 2016 10:30 AM EDT Reads: 749
Jul. 28, 2016 10:15 AM EDT Reads: 476
Jul. 28, 2016 10:00 AM EDT Reads: 255
Jul. 28, 2016 09:30 AM EDT Reads: 1,392
Jul. 28, 2016 09:28 AM EDT Reads: 179
Jul. 28, 2016 09:00 AM EDT Reads: 1,603
Jul. 28, 2016 08:30 AM EDT Reads: 356
Jul. 28, 2016 08:30 AM EDT Reads: 1,675
Jul. 28, 2016 07:45 AM EDT Reads: 919
Jul. 28, 2016 07:30 AM EDT Reads: 519
Jul. 28, 2016 07:15 AM EDT Reads: 695
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
Jul. 28, 2016 06:45 AM EDT Reads: 1,863
Jul. 28, 2016 06:45 AM EDT Reads: 1,559
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
Jul. 28, 2016 05:45 AM EDT Reads: 2,326
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Jul. 28, 2016 04:45 AM EDT Reads: 1,380